Sulphasalazine for rheumatoid arthritis: Toxicity in 774 patients monitored for one to 11 years

British Medical Journal (Clinical research ed.)

Volumn 293, Issue 6544, 1986, Pages 420-423

  Situnayake, D ^c   Mcconkey, B ^c  

^a Nether Edge Hospital   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; DIGESTIVE SYSTEM; DRUG THERAPY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INTOXICATION; JOINT; LEUKOPENIA; MAJOR CLINICAL STUDY; MEGALOBLASTIC ANEMIA; MOUTH; MOUTH ULCER; NERVOUS SYSTEM; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN TOXICITY; THERAPY;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; SULFASALAZINE; TIME FACTORS;

EID: 0022541810     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.293.6544.420     Document Type: Article

References (31)

1. McConkey B, Amos RS, Butler EP, Crockson RA, Crockson AP, Walsh L. Salazopyrin in rheumatoid arthritis. Agents Actions 1978;88:438-41.
2. McConkey B, Amos RS, Durham S, Forster PJG, Hubball S, Walsh L. Sulphasalazine in rheumatoid arthritis. Br Med J 1980;280:441-4.
3. Neumann VC, Grindulis KA, Hubball S, McConkey B, Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J 1983;287:1089-102.
4. Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double-blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 1984;287: 1102–4.
5. Bax DE, Amos RS, Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate. Ann Rheum Dis 1985;44:194-8.
6. Martin L, Sitar DS, Chalmers IM, Hunter T. Sulphasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity. J Rheumatol 1985;12:270-3.
7. Bax DE, Amos RS, Situnayake D, McConkey B. Sulphasalazine in rheumatoid arthritis. Lancet 1985;i: 1450.
8. Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis. Lancet 1985; i: 1167.
9. Das KM, Eastwood MA, McManus JPA, Sirius W. Adverse reactions during salicylazo-sulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1983;289:491-5.
10. Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J 1985;290:1535-8.
11. Situnayake D, McConkey B. Resin-coated 5-aminosalicylic acid (Asacol) in rheumatoid arthritis. Br J Rheumatol 1985; 24: 226-7.
12. Baker H. Drug reactions. In: Rook A, Wilkinson DS, Ebling FJG, eds. Textbook of dermatology. 3rd ed. Oxford: Blackwell Scientific Publications, 1979:1142-3.
13. Bax DE, Amos RS, Sulphasalazine in rheumatoid arthritis: desensitizing the patient with a skin rash. Ann Rheum Dis 1986;45:139-40.
14. Pullar T, Hunter JA, Capell HA. Toxicity of sulphasalazine in patients with rheumatoid arthritis. Br J Rheumatol 1985;24:214.
15. Davies GE, Palek J. Selective erythroid and megakaryocytic aplasia after sulphasalazine administration. Arch Intern Med 1980;140:1122.
16. Partridge REH, Duthie JJR, Incidence of macrocytic anaemia in rheumatoid arthritis. Br Med J 1963; i: 89–91.
17. Gough KR, McCarthy C, Read AE, Mollin DL, Waters AH. Folic acid deficiency in rheumatoid arthritis. Br Med J 1964; i: 212-7.
18. Omer A, Mowat AG. Nature of anaemia in rheumatoid arthritis. IX. Folate metabolism in patients with rheumatoid arthritis. Ann Rheum Dis 1968;27:414-24.
19. Omer A, Mowat AG. Nature of anaemia in rheumatoid arthritis. X. Folate-releasing properties of plasma in health and disease, with special reference to rheumatoid arthritis. Ann Rheum Dis 1969;28:24-7.
20. Franklin JL, Rosenberg IH, Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulphapyridine (Azulfidine). Gastroenterology 1973;64:517-25.
21. Selhub J, Dhar GJ, Rosenberg IH, Inhibition of folate enzymes by sulphasalazine. J Clin Invest 1978;61:221-4.
22. Schneider RE, Beeley L. Megaloblastic anaemia associated with sulphasalazine treatment. Br Med J 1977; i: 1638–9.
23. Grindulis KA, McConkey B. Does sulphasalazine cause folate deficiency in rheumatoid arthritis? Scand J Rheumatol 1985;14:265-70.
24. Jones GR, Malone DNS. Sulphasalazine induced lung disease. Thorax 1972;27:713-7.
25. Berliner S, Neeman A, Shoenfield Y, et al. Salazopyrin induced eosinophilic pneumonia. Respiration 1980;39:119-20.
26. Davies D, MacFarlane A. Fibrosing alveolitis and treatment with sulphasalazine. Gut 1974;15: 185–8.
27. Raforth RJ. Systemic granulomatous reaction to salicylazosulphapyridine (Azulfidine) in a patient with Crohn's disease. Am J Dig Dis 1974;19:465-9.
28. Kanner RS, Tedesco FJ, Kaiser MH. Azulfidine (sulphasalazine)-induced hepatic injury. Am J Dig Dis 1978;23:956-8.
29. Mihas AA, Goldenberg DJ, Slaughter RL. Sulfasalazine toxic reactions. Hepatitis, fever and skin rash with hypocomplementaemia and immune complexes. JAMA 1978;239:2590-1.
30. Chester AH, Diamond LH, Schreiner GE. Hypersensitivity to salicylazosulphapyridine. Renal and hepatic toxic reactions. Arch Intern Med 1978; 138: 1138-9.
31. Farr M, Symmons DPM, Bacon PA. Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine. Ann Rheum Dis 1985;44:798-800.